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Clinical and inflammatory determinants of
bronchial hyperresponsiveness in COPD
Maarten van den Berge*,#, Judith M. Vonk#,", Margot Gosman+, The´re`se
S. Lapperre1, Jiska B. Snoeck-Strobande, Peter J. Sterk**, Lisette I.Z. Kunz1,
Pieter S. Hiemstra1, Wim Timens#,##, Nick H.T. ten Hacken*,#,
Huib A.M. Kerstjens*,# and Dirkje S. Postma*,#
ABSTRACT: Bronchial hyperresponsiveness (BHR) is regarded as a hallmark of asthma, yet it is
also present in a considerable number of chronic obstructive pulmonary disease (COPD) patients.
Epidemiological studies have shown that BHR provides complementary information to forced
expiratory volume in 1 s (FEV1) for development and progression of COPD. We hypothesised that
the severity of BHR and its longitudinal changes associate with both clinical and airway
inflammation measures in COPD.
Our hypothesis was tested in 114 COPD patients (median age 62.9 years, smoking exposure
45.9 pack-yrs) participating in the GLUCOLD (Groningen Leiden Universities Corticosteroids in
Obstructive Lung Disease) study, which previously showed an improvement in BHR with
fluticasone and fluticasone/salmeterol. At baseline, and 6 and 30 months after treatment, we
investigated lung function, including body plethysmography, provocative concentration of
methacholine causing a 20% fall in FEV1, sputum induction, and bronchial biopsies.
By performing both cross-sectional and longitudinal analyses, we show that BHR in COPD is
predominantly associated with residual volume/total lung capacity (a measure of air trapping) and
airway inflammation reflected by the number of neutrophils, macrophages and lymphocytes in
sputum and bronchial biopsies.
Our findings indicate that BHR is an independent trait in COPD and provides important
information on phenotype heterogeneity and disease activity.
KEYWORDS: Bronchial biopsies, bronchial hyperresponsiveness, chronic obstructive pulmonary
disease, methacholine, neutrophils, sputum
C
hronic obstructive pulmonary disease
(COPD) has a major health impact through-
out the world [1, 2]. Patients with COPD
generally show a progressive lung function loss
with a concomitant reduction in health status and
increase in symptoms. Some of these symptoms,
such as a sudden increase in cough and dyspnoea
when inhaling cold, air are due to bronchial
hyperresponsiveness (BHR). BHR is often thought
to be a hallmark of asthma, yet it has been shown
to occur in up to two-thirds of patients with COPD
as well [3]. In asthma, BHR is associated with both
baseline level of forced expiratory volume in 1 s
(FEV1) and eosinophilic airway inflammation
measured in peripheral blood, sputum, bronch-
oalveolar lavage or bronchial biopsies [4, 5]. Thus
far, the factors underlying BHR in COPD remain
largely unknown. Since patients with COPD
invariably have airway obstruction that is often
quite severe, it has been argued that the presence
of BHR in COPD merely reflects a lower pre-
challenge FEV1 and is not of pathophysiological
importance [6, 7]. An argument against this
assumption is the observation that the presence
of BHR precedes the development of COPD-like
symptoms in the general population [8]. In
addition, a more severe BHR is associated with
an accelerated decline in lung function in COPD
patients even after adjusting for baseline FEV1
[9, 10]. Furthermore, the severity of BHR is an
independent predictor of improvement in FEV1
after smoking cessation in patients with mild-to-
moderate COPD participating in the Lung Health
Study [11]. Given these observations, it is impor-
tant to further explore the underlying physiology
of BHR in COPD.
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The GLUCOLD (Groningen Leiden Universities Corticoster-
oids in Obstructive Lung Disease) study showed an improve-
ment in FEV1 and BHR after treatment with fluticasone or
fluticasone/salmeterol for up to 30 months, and, at the same
time, improvements in inflammatory parameters in patients
with mild-to-moderate COPD [12]. We hypothesised that the
severity of BHR and its longitudinal changes are not only
associated with lung function, but also with the extent of
airway inflammation in patients with COPD. The GLUCOLD
study provides an excellent opportunity to investigate this,
since all patients were extensively characterised before, and 6
and 30 months after treatment with inhaled corticosteroids
(ICSs) with or without a long-acting b-agonist, or placebo.
METHODS
Patients
114 with COPD participating in the GLUCOLD study were
included [12]. The GLUCOLD study enrolled patients with
COPD in Global Initiative for Chronic Obstructive Lung Disease
stages II and III who were aged 40–75 yrs and current or former
smokers with o10 pack-yrs smoking exposure. Exclusion
criteria were a history of asthma and the use of ICSs and oral
corticosteroids within 6 months prior to the start of the study.
Study design
The study design of the GLUCOLD study has been described
in detail previously [12]. In brief, patients were randomly
assigned to receive one out of four double-blind treatments: 1)
fluticasone (500 mg) b.i.d. for 30 months; 2) fluticasone/salme-
terol (500/50 mg) b.i.d. for 30 months; 3) fluticasone (500 mg)
b.i.d. for the first 6 months followed by placebo b.i.d. for
24 months; or 4) placebo b.i.d. for 30 months (fig. 1). At baseline,
and after 6 and 30 months of treatment, the following investi-
gations were performed: spirometry; body plethysmography;
provocative concentration of methacholine causing a fall in
FEV1 of 20% (PC20); blood collection; sputum induction; and
bronchoscopy with bronchial biopsies. The study was carried
out in two Dutch centres (University Medical Center Groningen
and the Leiden University Medical Center). Both centres’ ethics
committees approved the study and all patients provided
written informed consent.
Lung function and BHR
FEV1 was measured with a daily-calibrated pneumotachograph
(Masterscreen Pneumo; Jaeger, Wurzburg, Germany) according
to standardised guidelines. Methacholine PC20 was measured by
the 2-min tidal breathing method as described previously [13].
Patients were considered to be hyperresponsive when they had a
methacholine bromide PC20 f9.6 mg?mL-1, corresponding to a
methacholine chloride PC20 ,8 mg?mL-1 on a molar basis [13].
Total lung capacity (TLC), residual volume (RV) and inspira-
tory capacity were measured using a constant volume body
plethysmograph according to standardised guidelines [14].
Sputum induction and sputum processing
Sputum was induced by inhalation of hypertonic saline
aerosols as previously described [15]. 15 min after salbutamol
(200 mg) inhalation, 4.5% hypertonic saline was nebulised three
times over 5 min. Whole samples were processed according to
the method described by FAHY et al. [16].
Bronchoscopic biopsy analyses
The methods for biopsy processing, staining and analysis have
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FIGURE 1. Total number of randomised patients who adhered to therapy per treatment group. #: .70% medication use. Reproduced and modified from [12] with
permission from the publisher.
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paraffin-embedded sections were stained using specific anti-
bodies against T-lymphocytes (anti-CD4 and anti-CD8), macro-
phages (anti-CD68), neutrophil elastase, mast cell tryptase (AA1),
eosinophils (EG2) and plasma cells (anti-CD138). Digital images
per coded biopsy section were prepared using a colour camera
(A101fc-le; Basler AG, Ahrensburg, Germany) and a dedicated
software program (RVC Software, Amersfoort, The Netherlands).
These images were united into one large image consisting of
the entire biopsy section (100 mm, 115.7 pixels). Numbers of
subepithelial, positively staining inflammatory cells were counted
within the largest possible area,f125 mm beneath the basement
membrane, per biopsy section, and expressed as the mean
number of cells per 0.1 mm2 of two tissue samples per patient.
Statistical analysis
Mean¡SD or median (interquartile range) of variables were
calculated. When appropriate, variables were normalised by
logarithmic transformation before statistical analysis. PC20
calculations were performed using the base-2 logarithm (log2),
as this reflects doubling concentrations and normalises the
distribution [18]. We performed analyses on PC20 at baseline,
and on the changes in PC20 during the first 6 months of treat-
ment, and between 6 and 30 months of treatment. Univariate
analyses were performed in all patients from all treatment
groups. Subsequently, multivariate linear regression analysis
was performed in the full cohort with baseline or change in
methacholine PC20 as the dependent variable, and age, sex,
treatment group and smoking status (current or ex-smoker) as
covariates. In addition, we included those variables with the
most significant univariate regression coefficients in each of the
following categories: 1) lung function; 2) blood cell differential
count; 3) sputum cell differential count; and 4) inflammatory
cells in bronchial biopsies.
RESULTS
Participants
A total of 114 patients with COPD were included in the study.
Methacholine PC20 was not determined in four patients because
their baseline FEV1 was ,1.2 L. The baseline characteristics of
the remaining 110 patients are presented in table 1. The sputum
sample was discarded in eight patients, as it contained .80%
squamous cells. A bronchoscopy was performed in all patients;
one patient had no adequate sample. Blood was collected in all
patients. A complete dataset was available for 74 of the 114
patients at baseline. After treatment, 19 patients were with-
drawn from further analyses because they did not meet the pre-
defined criteria for treatment compliance or withdrew their
consent (n56). Of the remaining 95 patients, a sputum sample of
sufficient quality was obtained in 87 and 80 patients after 6 and
30 months of treatment, and a bronchoscopy was performed in
90 and 77 patients, respectively.
Cross-sectional analysis of methacholine PC20 at baseline
From the 110 patients with a methacholine PC20 available at
baseline, a total of 103 (94%) were hyperresponsive. Patients
with BHR were more often female, had a higher RV/TLC %
predicted, a higher number of sputum eosinophils and tended
to have a lower FEV1/inspiratory vital capacity (IVC) ratio
than patients without BHR.
Univariate associations with clinical and inflammatory
parameters at baseline
At baseline, higher methacholine PC20 values, i.e. less severe
BHR was associated with a higher post-bronchodilator FEV1 %
pred, FEV1/IVC, forced expiratory flow (FEF) at 50% of forced
vital capacity (FVC) % pred and 75% of FVC % pred, and a
lower reversibility and RV/TLC % pred (fig. 2 and table S1).
For example, for every per cent increase in RV/TLC % pred,
the severity of BHR increased with a doubling concentration of
0.04, and for every 105 increase in the number of neutrophils
per millilitre, the severity of BHR increased with doubling
concentration of 1.87 (table S1).
A lower methacholine PC20, i.e. more severe BHR, was associated
with higher numbers of sputum neutrophils, macrophages,
lymphocytes and eosinophils.
TABLE 1 Baseline characteristics and cell count data of
the study population
Age yrs 62.9 (57.0–68.0)
Males/females n 96/14
Current smokers % 63
Smoking exposure pack-yrs 41.8 (31.2–54.8)
Body mass index kg?m-2 25.3 (22.4–27.8)
Methacholine PC20 mg?mL-1
geometric mean (interquartile range)
1.8 (0.2–2.4)
FEV1# % pred 64.2 (57.1–69.3)
FVC# % pred 99.0 (91.3–109.9)
FEV1/IVC# % 45.2 (39.3–52.7)
RV/TLC# % pred 125.6 (112.6–140.3)
IC % pred 72.1 (62.7–83.9)













Bronchial epithelial cells 0.4 (0.2–0.6)




CD4+ cells 1.7 (1.4–1.9)
CD8+ cells 1.3 (1.1–1.6)
Mast cells 1.4 (1.3–1.5)
Data are expressed as median (interquartile range), unless otherwise stated.
PC20: provocative concentration causing a 20% fall in FEV1; FEV1: forced
expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; IVC:
inspiratory vital capacity; RV: residual volume; TLC: total lung capacity; IC:
inspiratory capacity; TL,CO: transfer factor of the lung for carbon monoxide; VA:
alveolar volume. #: post-bronchodilator; ": log transformed.
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Multivariate linear regression with clinical and inflammatory
variables
Females had more severe BHR than males, independent of
their baseline level of airway obstruction, age or smoking status.
In addition, more severe BHR was independently associated
with both a lower FEV1/IVC and a higher number of sputum
neutrophils (table 2). When replacing the number of sputum
neutrophils with other sputum cell counts that associated with
methacholine PC20 with a p-value ,0.1, a higher number of
sputum lymphocytes was the single factor contributing inde-
pendently to the severity of methacholine PC20 (b -0.27, 95% CI
-4.55– -0.81).
Analysis on change in methacholine PC20 during the first
6 months
No significant associations existed between the change in
methacholine PC20 during the 6-month treatment and the change
in post-bronchodilator FEV1 % pred or post-bronchodilator
FEV1/IVC (table S2). Improvement in methacholine PC20 was
associated with reduction in RV/TLC % pred and increase in
percentage of blood monocytes. Furthermore, improvement in
methacholine PC20 was associated with a decrease in the number
of sputum neutrophils, but not with other numbers of inflam-
matory cells in sputum. Finally, improvement in methacholine
PC20 was associated with reduction in the number of CD4+ cells
in bronchial biopsies.
Multivariate linear regression with changes in clinical and
inflammatory variables
Improvement in methacholine PC20 was significantly and
independently associated with a decrease in RV/TLC % pred
and an increase in the percentage of blood monocytes (table 3).
In addition, improvement in methacholine PC20 tended to
associate with a decrease in the number of neutrophils in







Log sputum neutrophils ×104 cells·mL-1
3
-10 0
ΔFEV1 0–6 months % pred
10 -40 0 40
ΔRV/TLC 0–6 months % pred
80 -1 0




ΔFEV1 6–30 months % pred
2010 -80 -40 0
ΔRV/TLC 6–30 months % pred
40 -2 0-1



























































































































































































FIGURE 2. Univariate associations between: baseline provocative concentration of methacholine causing a 20% fall in forced expiratory volume in 1 s (PC20), and a)
forced expiratory volume in 1 s (FEV1), b) residual volume (RV)/total lung capacity (TLC) and c) the number of sputum neutrophils; change in (D) methacholine PC20 between
0 and 6 months of treatment, and d) DFEV1, e) DRV/TLC and f) change in the number of sputum neutrophils; and change in methacholine PC20 between 6 and 30 months of
treatment, and g) DFEV1, h) DRV/TLC and i) change in the number of sputum neutrophils. % pred: % predicted.
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Analysis on changes in methacholine PC20 between 6 and
30 months of treatment with changes in clinical and
inflammatory parameters
A larger improvement in methacholine PC20 associated with a
greater reduction in RV/TLC % pred (fig. 2 and table S2).
Furthermore, improvement in methacholine PC20 was asso-
ciated with decreases in the number of sputum total cells,
neutrophils, eosinophils, macrophages and lymphocytes.
Multivariate linear regression with changes in clinical and
inflammatory variables
Multivariate analysis showed that being an ex-smoker, greater
reduction in RV/TLC % pred and sputum macrophages
independently associated with better improvement in methacho-
line PC20. These findings were corroborated by the observation
that the severity of methacholine PC20 increased when patients
were switched from fluticasone to placebo (table 4). When
replacing the change in the number of sputum macrophages
with changes in other sputum cells that were significantly
associated with changes in methacholine PC20 in the univariate
analyses, reductions in the number of sputum lymphocytes and
neutrophils, but not total sputum cell counts, were indepen-
dently associated with improvements in BHR (b -1.56 (95% CI
-2.69– -0.42), -1.33 (95% CI -2.40– -0.27) and -1.11 (95% CI -2.30–
0.08), respectively).
DISCUSSION
Our data show that a more severe BHR in COPD is associated
with a higher degree of airway obstruction as reflected by lower
FEV1 and FEV1/IVC values. This can be explained by the simple
fact that the same bronchoconstrictor response results in a larger
drop in FEV1 in a subject with more severe airway obstruction [3,
18–20]. Interestingly, we additionally show that more severe BHR
is independently associated with airway inflammation in COPD,
as reflected by higher numbers of sputum neutrophils, even after
adjusting for age, sex, smoking status and baseline level of airway
obstruction. Moreover, we performed a longitudinal analysis,
which revealed that both short-term (6 months) and long-term
(between 6 and 30 months) treatment-induced improvements in
BHR were independently associated with reductions in numbers
of sputum neutrophils, macrophages and lymphocytes.
Many researchers and clinicians consider BHR to be a hallmark
of asthma but not of COPD. Our data show that BHR is also
present in a considerable proportion of COPD patients. This is
in agreement with the findings two earlier studies. First, the
Lung Health Study reported a prevalence of BHR of ,60% in
COPD [3]. Secondly, WALKER et al. [21] investigated the effects of
methacholine inhalation on respiratory mechanics and found
hyperresponsiveness to be present in all 25 included COPD
patients. Taking these findings into account, the high prevalence
of 94% for BHR in the GLUCOLD study may not be surprising.
Importantly, we specifically excluded patients with asthma by
carefully reviewing family charts for earlier diagnosis of asthma,
and with an interview and physical examination by a pulmonary
physician. In addition, the diagnosis of COPD was verified
by including only patients .45 yrs with a smoking history
o10 pack-yrs.
In asthma, several studies have shown that the severity of BHR
and its treatment-induced improvement is associated with
(reduction in) eosinophilic airway inflammation [4, 18, 22].
This contrasts with our findings in COPD. We observed a strong
and independent association between BHR and neutrophilic
airway inflammation, as reflected by the number of sputum
neutrophils both in cross-sectional and longitudinal analyses.
This is in agreement with our earlier observations that increased
superoxide anion production in peripheral blood neutrophils
TABLE 2 Multivariate regression analysis on the
association between provocative concentration
of methacholine causing a 20% fall in forced
expiratory volume in 1 s (PC20), and clinical and
inflammatory variables in blood, sputum and
bronchial biopsies at baseline
Methacholine log2 PC20 p-value
Current smoker 0.10 (-1.00–1.19) 0.862
Age yrs -0.05 (-0.11–0.02) 0.187
Female sex -2.86 (-4.47– -1.26) 0.001
FEV1/IVC# % 0.10 (0.03–0.16) 0.004
TL,CO/VA % pred 0.002 (-0.02–0.026) 0.846
Blood monocytes % -0.16 (-0.37–0.05) 0.138
Sputum neutrophils6104 cells?mL-1",+ -1.18 (-2.25– -0.11) 0.032
Bronchial CD4+ cells per 0.1 mm2" -0.50 (-2.15–1.15) 0.546
Data are presented as b (95% CI), unless otherwise stated. Bold indicated
statistically significant values. FEV1: forced expiratory volume in 1 s; IVC:
inspiratory vital capacity; TL,CO: transfer factor of the lung for carbon monoxide;
VA: alveolar volume; % pred: % predicted. #: post-bronchodilator; ": log
transformed; +: b -1.67 (95% CI -3.13– -0.22) for sputum lymphocytes (p50.025).
TABLE 3 Multivariate regression analysis on the
association between change in (D) provocative
concentration of methacholine causing a 20% fall
in forced expiratory volume in 1 s (PC20) after the
6-month treatment, and the change in clinical
and inflammatory variables in blood, sputum and
bronchial biopsies
Methacholine Dlog2 PC20 p-value
Current smoker -0.66 (-1.83–0.52) 0.268
Age yrs -0.30 (-1.04–0.04) 0.423
Female sex 0.26 (-1.67–1.72) 0.976
Treatment group
Fluticasone/salmeterol 0.07 (-1.70–1.85) 0.936
Fluticasone 0.36 (-1.09–1.81) 0.622
DRV/TLC % pred -0.03 (-0.06–0.00) 0.050
D blood monocytes % 0.35 (0.10–0.59) 0.006
D sputum neutrophils6104 cells?mL-1# -0.98 (-2.06–0.11) 0.076
D bronchial CD4+ cells per 0.1 mm2# -0.93 (-2.14–0.27) 0.128
Data are presented as b (95% CI), unless otherwise stated. Bold indicates
statistically significant values. RV: residual volume; TLC: total lung capacity; %
pred: % predicted. #: log transformed.
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associates with more severe BHR in patients with COPD [23].
There is extensive evidence that neutrophils are important
effector cells in COPD. In this context, the findings of BARALDO
et al. [24] are of interest. They found that neutrophils infiltrate
the airway smooth muscle of patients with COPD to a greater
extent than in healthy subjects and this higher degree of
neutrophilic infiltration was associated with a lower FEV1. The
latter is not surprising, since neutrophils are able to release a
variety of pro-inflammatory mediators, including elastase,
leukotriene B4, myeloperoxidase, defensins, cathepsin G and
tumour necrosis factor-a. This may lead to damage of the
epithelium and lung extracellular matrix, increased mucus
secretion, increased permeability of the bronchial mucosa with
associated airway wall thickening, and an increased contractile
status of airway smooth muscle cells, all contributing to a lower
FEV1 and more severe BHR [25].
Furthermore, in our study, improvements in BHR during the
last 2 yrs of treatment were independently associated with
decreases in the number of sputum macrophages and lympho-
cytes, indicating that these cells are also important factors
contributing to BHR. Taken together, we have now clearly
shown that BHR is not merely a surrogate marker for airway
obstruction, but also reflects the inflammatory process under-
lying COPD. Interestingly, improvement in BHR in patients
with COPD was not associated with reduction in eosinophilic
airway inflammation, as is the case in asthma, again reflecting
that the mechanisms underlying BHR are very different
between asthma and COPD.
To our surprise, we did not find an independent association
between improvement in BHR and reduction in airway obstruc-
tion as reflected by FEV1 or FEV1/IVC. Interestingly, reduction in
RV/TLC % pred was of importance. This could be due to either a
decrease in airway resistance or a reduction in air trapping due
to closure of the large and/or small airways. In line with
this, HARDAKER et al. [26] showed that an increased RV was a
significant independent predictor of BHR in older patients with
asthma. In addition, WAGERS et al. [27] showed in a mouse model
that airway closure is a central factor contributing to BHR in
asthma [28]. The findings of our study suggest that airway
closure also contributes BHR in COPD.
We have previously demonstrated that fluticasone and flutica-
sone/salmeterol significantly improve BHR both after 6-month
treatment and 6–30-month treatment [12]. However, in the
current multivariate regression analysis, treatment with flutica-
sone or fluticasone/salmeterol was not independently asso-
ciated with improvement in BHR, suggesting that treatment-
induced improvement is, at least partly, mediated via reduction
in both hyperinflation and airway inflammation.
Similar to findings by KANNER et al. [29], we found that female
patients with COPD have more severe BHR than males even after
adjustment for baseline airway obstruction. This is especially
remarkable given the low number of females in our study. Thus
far, the reason why females have more severe BHR is unclear. A
possible explanation might be that females have a different type
of COPD. It has been shown using computed tomography and
histological examination of resected lung specimens that female
patients have less emphysema, but thicker bronchiolar airway
walls with disproportionately reduced lumens compared to
males [30]. Alternatively, hormone-related events may play a role
in the development and severity of BHR in COPD [31]. We have
extended the findings of KANNER et al. [29] by also investigating
the longitudinal changes in BHR after 6- and 30-month treatment.
In this way, we were able to show that the level of BHR improved
to a similar extent after treatment in males and females with
COPD.
The observation that an increase in peripheral blood monocytes
after 6-month treatment was independently associated with a
decrease in methacholine PC20 was unexpected and intriguing.
In this context, our previous findings in asthma are of interest,
showing that a higher percentage of peripheral blood mono-
cytes is associated with less severe BHR [4]. Although it has
been suggested that peripheral blood monocytes may play a role
in the immune responses, relatively little is known about their
relation to BHR in asthma or COPD. Therefore, our finding
merits further investigation.
Correlations between treatment-induced changes of methacho-
line PC20 and airway inflammation in patients participating in
the GLUCOLD study have been presented previously [12].
Changes in mast cells and CD4+ cells associated with change in
PC20 in univariate analyses. The previous report only included
subgroups of COPD patients using fluticasone or placebo for
30 months, whereas we have now analysed patients from all
four treatment groups. In addition, the previous report
assessed the change in BHR between 0 and 30 months, while
we now analysed the change between 0–6 and 6–30 months.
The latter time-points were chosen because a subgroup of
TABLE 4 Multivariate regression analysis of the
association between change in (D) provocative
concentration of methacholine causing a 20% fall
in forced expiratory volume in 1 s (PC20) between
6- and 30-month treatment, and the changes in





Current smoker -1.96 (-3.35– -0.58) 0.006
Age yrs -0.05 (-0.13–0.04) 0.259
Female sex 0.11 (-2.48–2.69) 0.934
Treatment group
Fluticasone/salmeterol -0.94 (-2.77–0.90) 0.310
Fluticasone
6 months -2.43 (-4.14– -0.73) 0.006
30 months -0.12 (-1.80–1.56) 0.887
DRV/TLC % pred -0.04 (-0.08– -0.07) 0.021
D sputum macrophages
6104 cells?mL-1#,"
-1.72 (-2.78– -0.68) 0.002
Data are presented as b (95% CI), unless otherwise stated. Bold indicates
statistically significant values. RV: residual volume; TLC: total lung capacity; %
pred: % predicted. #: log transformed; ": b -1.56 (95% CI -2.69– -0.42) for
sputum lymphocytes (p50.008), -1.33 (95% CI -2.40– -0.27) for sputum
neutrophils (p50.015) and -1.11 (95% CI -2.30–0.08) for total number of cells
in sputum (p50.066).
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patients participating in the GLUCOLD study was treated with
fluticasone for the first 6 months followed by placebo during
the second 24 months. Compatible with our previous report,
univariate regression analysis showed that improvement in
methacholine PC20 after 6 months was associated with a
reduction in the number of CD4+ cells in bronchial biopsies
and tended to associate with reduction in mast cells (p50.002
and p50.06, respectively; table S2). However, the current
multivariate analyses did not show any associations between
the number of CD4+ lymphocytes or mast cells and the severity
of BHR at baseline, or between reductions in CD4+ lymphocytes
or mast cells and improvements in BHR between 6- and 30-
month treatment. In addition, the number of CD4+ lymphocytes
or mast cells did not contribute independently to improvement
of BHR. Thus, in contrast to asthma, our findings do not suggest
a large contribution of CD4+ lymphocytes or mast cells to the
severity of BHR in COPD, but rather highlight the contribution
of sputum neutrophils, lymphocytes and macrophages [32, 33].
In conclusion, the results of our study improve the knowledge
on BHR in COPD even though the dispersion of our data is such
that it leaves room for additional mechanisms/interactions
explaining the mysterious relationship between lung function
and biology in COPD. We show that BHR is not only a hallmark
of asthma but also occurs in many patients with moderately
severe COPD who do not use inhaled corticosteroids. Never-
theless, the factors underlying BHR seem to be different in
asthma and COPD. In asthma, the severity of BHR and its
treatment-induced improvement have been shown to be
associated with (reduction in) the number of eosinophils and
mast cells in sputum and bronchial biopsies [4, 18, 22]. This
contrasts with our findings in COPD. By performing both cross-
sectional and longitudinal analyses, we were able to show, for
the first time, that BHR in COPD is predominantly associated
with airway inflammation reflected by numbers of neutrophils,
lymphocytes and macrophages in sputum and bronchial
biopsies. In addition, the longitudinal analysis showed that
RV/TLC, a measure of air trapping, rather than airflow
obstruction contributes to BHR in COPD. Our data indicate that
BHR is an independent trait in COPD and provides additional
information on phenotype and disease activity. The role of BHR
in COPD deserves further investigation in epidemiological,
pathological and pharmacological studies.
SUPPORT STATEMENT
This study was funded by the Netherlands Organization for Scientific
Research (NWO), the Dutch Asthma Foundation, GlaxoSmithKline, the
University Medical Center Groningen and Leiden University Medical
Center.
STATEMENT OF INTEREST
Statements of interest for M. van den Berge, T.S. Lapperre, P.J. Sterk,
P.S. Hiemstra, N.H.T. ten Hacken, H.A.M. Kerstjens and D.S. Postma,
and for the study itself can be found at www.erj.ersjournals.com/site/
misc/statements.xhtml
REFERENCES
1 Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive
pulmonary disease surveillance – United States, 1971–2000.
MMWR Surveill Summ 2002; 51: 1–16.
2 Murray CJ, Lopez AD. Mortality by cause for eight regions of
the world: Global Burden of Disease Study. Lancet 1997; 349:
1269–1276.
3 Tashkin DP, Altose MD, Bleecker ER, et al. The lung health study:
airway responsiveness to inhaled methacholine in smokers with
mild to moderate airflow limitation. The Lung Health Study
Research Group. Am Rev Respir Dis 1992; 145: 301–310.
4 van den Berge M, Meijer RJ, Kerstjens HAM, et al. PC20 adenosine
5’-monophosphate is more closely associated with airway inflam-
mation in asthma than PC20 methacholine. Am J Respir Crit Care
Med 2001; 163: 1546–1550.
5 Wardlaw AJ, Dunnette S, Gleich GJ, et al. Eosinophils and mast
cells in bronchoalveolar lavage in subjects with mild asthma.
Relationship to bronchial hyperreactivity. Am Rev Respir Dis 1988;
137: 62–69.
6 Ramsdale EH, Hargreave FE. Differences in airway responsive-
ness in asthma and chronic airflow obstruction. Med Clin North Am
1990; 74: 741–751.
7 Postma DS, Kerstjens HAM. Characteristics of airway hyperre-
sponsiveness in asthma and chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 1998; 158: S187–S192.
8 Xu X, Rijcken B, Schouten JP, et al. Airways responsiveness and
development and remission of chronic respiratory symptoms in
adults. Lancet 1997; 350: 1431–1434.
9 Postma DS, de Vries K, Koeter GH, et al. Independent influence of
reversibility of air-flow obstruction and nonspecific hyperreactiv-
ity on the long-term course of lung function in chronic air-flow
obstruction. Am Rev Respir Dis 1986; 134: 276–280.
10 Tashkin DP, Altose MD, Connett JE, et al. Methacholine reactivity
predicts changes in lung function over time in smokers with early
chronic obstructive pulmonary disease. The Lung Health Study
Research Group. Am J Respir Crit Care Med 1996; 153: 1802–1811.
11 Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and
lung function in mild-to-moderate chronic obstructive pulmonary
disease. The Lung Health Study. Am J Respir Crit Care Med 2000;
161: 381–390.
12 Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of
fluticasone with and without salmeterol on pulmonary outcomes
in chronic obstructive pulmonary disease: a randomized trial. Ann
Intern Med 2009; 151: 517–527.
13 Cockcroft DW. Direct challenge tests: Airway hyperresponsive-
ness in asthma: its measurement and clinical significance. Chest
2010; 138: 18S–24S.
14 Quanjer PH, Tammeling GJ, Cotes JE, et al. Symbols, abbreviations
and units. Working Party Standardization of Lung Function Tests,
European Community for Steel and Coal. Eur Respir J 1993; 6:
Suppl. 16, 5–40.
15 van den Berge M, Kerstjens HAM, de Reus DM, et al. Provocation
with adenosine 59-monophosphate, but not methacholine, induces
sputum eosinophilia. Clin Exp Allergy 2004; 34: 71–76.
16 Fahy JV, Liu J, Wong H, et al. Cellular and biochemical analysis of
induced sputum from asthmatic and from healthy subjects. Am
Rev Respir Dis 1993; 147: 1126–1131.
17 Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Dissociation
of lung function and airway inflammation in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2004; 170: 499–504.
18 van den Berge M, Kerstjens HAM, Meijer RJ, et al. Corticosteroid-
induced improvement in the PC20 of adenosine monophosphate is
more closely associated with reduction in airway inflammation
than improvement in the PC20 of methacholine. Am J Respir Crit
Care Med 2001; 164: 1127–1132.
19 Willemse BW, Ten Hacken NH, Rutgers B, et al. Smoking cessation
improves both direct and indirect airway hyperresponsiveness in
COPD. Eur Respir J 2004; 24: 391–396.
20 Kuwano K, Bosken CH, Pare PD, et al. Small airways dimensions
in asthma and in chronic obstructive pulmonary disease. Am Rev
Respir Dis 1993; 148: 1220–1225.
COPD M. VAN DEN BERGE ET AL.
1104 VOLUME 40 NUMBER 5 EUROPEAN RESPIRATORY JOURNAL
21 Walker PP, Hadcroft J, Costello RW, et al. Lung function changes
following methacholine inhalation in COPD. Respir Med 2009; 103:
535–541.
22 Sont JK, Willems LN, Bel EH, et al. Clinical control and
histopathologic outcome of asthma when using airway hyperre-
sponsiveness as an additional guide to long-term treatment. The
AMPUL Study Group. Am J Respir Crit Care Med 1999; 159:
1043–1051.
23 Postma DS, Renkema TE, Noordhoek JA, et al. Association
between nonspecific bronchial hyperreactivity and superoxide
anion production by polymorphonuclear leukocytes in chronic air-
flow obstruction. Am Rev Respir Dis 1988; 137: 57–61.
24 Baraldo S, Turato G, Badin C, et al. Neutrophilic infiltration within
the airway smooth muscle in patients with COPD. Thorax 2004; 59:
308–312.
25 Schmidt D, Rabe KF. Immune mechanisms of smooth muscle
hyperreactivity in asthma. J Allergy Clin Immunol 2000; 105:
673–682.
26 Hardaker KM, Downie SR, Kermode JA, et al. Predictors of airway
hyperresponsiveness differ between old and young patients with
asthma. Chest 2011; 139: 1395–1401.
27 Wagers S, Lundblad LK, Ekman M, et al. The allergic mouse model
of asthma: normal smooth muscle in an abnormal lung? J Appl
Physiol 2004; 96: 2019–2027.
28 Irvin CG, Bates JH. Physiologic dysfunction of the asthmatic lung:
what’s going on down there, anyway?Proc Am Thorac Soc 2009; 6:
306–311.
29 Kanner RE, Connett JE, Altose MD, et al. Gender difference in
airway hyperresponsiveness in smokers with mild COPD. The
Lung Health Study. Am J Respir Crit Care Med 1994; 150: 956–961.
30 Martinez FJ, Curtis JL, Sciurba F, et al. Sex differences in severe
pulmonary emphysema. Am J Respir Crit CareMed 2007; 176: 243–252.
31 Han MK, Postma D, Mannino DM, et al. Gender and chronic
obstructive pulmonary disease: why it matters. Am J Respir Crit
Care Med 2007; 176: 1179–1184.
32 Ali FR, Kay AB, Larche M. Airway hyperresponsiveness and
bronchial mucosal inflammation in T cell peptide-induced asth-
matic reactions in atopic subjects. Thorax 2007; 62: 750–757.
33 Gonzalo JA, Qiu Y, Lora JM, et al. Coordinated involvement of
mast cells and T cells in allergic mucosal inflammation: critical role
of the CC chemokine ligand 1:CCR8 axis. J Immunol 2007; 179:
1740–1750.
M. VAN DEN BERGE ET AL. COPD
EUROPEAN RESPIRATORY JOURNAL VOLUME 40 NUMBER 5 1105
